The association between ADIPOQ gene variants (rs266729, rs2241766, rs1501299) and acute myocardial infarction in Vietnamese patients with type 2 diabetes mellitus

Abstract

Background: Type 2 diabetes mellitus (T2DM) significantly increases the risk of acute myocardial infarction (AMI). Polymorphisms in the ADIPOQ gene, which encodes the adiponectin hormone, are believed to influence cardiovascular disease risk. This study aims to evaluate the association between three ADIPOQ gene variants—rs266729, rs2241766, and rs1501299—and the risk of AMI in Vietnamese patients with T2DM. Methods: Acase–control study was conducted from January 2023 to June 2024 at the University Medical Center, Ho Chi Minh City. The study included 275 T2DM patients with a history of AMI (case group) and 275 T2DM patients without AMI (control group). Participants were matched by age, gender, smoking status, and duration of T2DM to control for potential confounding factors. DNA was extracted from peripheral blood samples, and the three polymorphisms were genotyped using Sanger sequencing. Results: Significant associations were found between ADIPOQ gene polymorphisms and AMI risk. The G/G genotype of rs266729 and the T/T genotype of rs1501299 were associated with a reduced risk of AMI (OR = 0.45, 95% CI [0.23–0.89], p = 0.021; OR = 0.45, 95% CI [0.22–0.90], p = 0.025, respectively). In contrast, the T/Ggenotype of rs2241766 was significantly associated with an increased risk of AMI (OR = 2.07, 95% CI [1.44–2.97], p < 0.001). Conclusion: This study suggests that rs266729 and rs1501299 may have protective effects, while rs2241766 may increase the risk of AMI in Vietnamese patients with T2DM. These findings highlight the importance of further research into adiponectin levels and long-term monitoring, and support the potential use of genetic variants in personalized cardiovascular risk management for patients with T2DM.